Table 4.
Predictors of Sustained Virologic Response by Genotypea in Multivariable Logistic Regression Models
| All patients
|
Genotype 1
|
Genotype 2
|
Genotype 3
|
|||||
|---|---|---|---|---|---|---|---|---|
| AORb | P value | AORb | P value | AORb | P value | AORb | P value | |
| Age | ||||||||
| <55 y | 1 | 1 | 1 | 1 | ||||
| 55 to <60 y | 0.88 | .2 | 0.87 | .3 | 1.37 | .2 | 0.58 | .01 |
| 60 to <65 y | 0.95 | .6 | 0.84 | .2 | 1.61 | .05 | 0.73 | .2 |
| 65 to <70 y | 0.95 | .6 | 0.86 | .3 | 1.20 | .5 | 1.12 | .7 |
| 70 to <75 y | 0.91 | .6 | 0.86 | .5 | 1.41 | .4 | 0.81 | .7 |
| ≥75 y | 1.62 | .2 | 1.22 | .7 | 3.04 | .09 | NA | |
| Race/ethnicity | ||||||||
| White, non-Hispanic | 1 | 1 | 1 | 1 | ||||
| Black, non-Hispanic | 0.81 | .004 | 0.83 | .02 | 0.49 | .001 | 0.76 | .5 |
| Hispanic | 0.79 | .05 | 0.72 | .04 | 1.14 | .7 | 0.80 | .4 |
| Asian, Pacific Islander, American Indian | 0.93 | .7 | 0.84 | .5 | 0.67 | .4 | 1.77 | .3 |
| Declined to answer, missing | 0.92 | .4 | 0.76 | .01 | 1.42 | .1 | 1.31 | .3 |
| Sex | ||||||||
| Female | 1 | 1 | 1 | 1 | ||||
| Male | 0.58 | .01 | 0.55 | .02 | 0.42 | .1 | 0.98 | .97 |
| Alcohol use disorder | ||||||||
| No | 1 | 1 | 1 | 1 | ||||
| Yes | 0.93 | .2 | 0.91 | .2 | 1.0 | 1.0 | 0.98 | .9 |
| Diabetes | ||||||||
| No | 1 | 1 | 1 | 1 | ||||
| Yes | 0.81 | .001 | 0.89 | .1 | 0.69 | .01 | 0.66 | .01 |
| Regimenc | ||||||||
| LDV/SOF | NA | NA | 1 | NA | NA | NA | NA | |
| LDV/SOF+ribavirin | NA | NA | 1.51 | .001 | NA | NA | 1 | |
| PrOD | NA | NA | 0.63 | .3 | NA | NA | NA | NA |
| PrOD+ribavirin | NA | NA | 1.04 | .9 | NA | NA | NA | NA |
| SOF+ribavirin | NA | NA | NA | NA | NA | NA | 0.78 | .04 |
| PEG+SOF+ribavirin | NA | NA | NA | NA | NA | NA | 2.65 | .001 |
| Genotype | ||||||||
| 1 | 1 | NA | NA | NA | NA | NA | NA | |
| 2 | 0.43 | <.001 | NA | NA | NA | NA | NA | NA |
| 3 | 0.23 | <.001 | NA | NA | NA | NA | NA | NA |
| 4 | 0.59 | .08 | NA | NA | NA | NA | NA | NA |
| Subgenotype | ||||||||
| a | NA | 1 | 1 | 1 | ||||
| b | NA | NA | 1.33 | .001 | 0.82 | .7 | NA | NA |
| None | NA | NA | 1.42 | .006 | 0.65 | .4 | NA | NA |
| HCV RNA viral load | ||||||||
| ≤6 million IU/mL | 1 | 1 | 1 | 1 | ||||
| >6 million IU/mL | 0.92 | .3 | 0.83 | .04 | 1.53 | .02 | 0.83 | .4 |
| Cirrhosis | ||||||||
| No | 1 | 1 | 1 | 1 | ||||
| Yes | 0.80 | .002 | 0.88 | .1 | 0.62 | .007 | 0.67 | .03 |
| Prior treatment | ||||||||
| Treatment-naïve | 1 | 1 | 1 | 1 | ||||
| Treatment-experienced | 0.92 | .2 | 1.02 | .8 | 0.59 | .001 | 0.69 | .02 |
| Platelet count | ||||||||
| ≥100 k/μL | 1 | 1 | 1 | 1 | ||||
| <100 k/μL | 0.74 | <.001 | 0.81 | .06 | 0.46 | <.001 | 0.84 | .4 |
| Serum bilirubin | ||||||||
| ≤1.1 g/dL | 1 | 1 | 1 | 1 | ||||
| >1.1 g/dL | 0.81 | .01 | 0.86 | .06 | 0.83 | .3 | 0.78 | .2 |
| Serum albumin | ||||||||
| ≥3.6 g/dL | 1 | 1 | 1 | 1 | ||||
| <3.6 g/dL | 0.81 | .003 | 0.79 | .007 | 1.13 | .5 | 0.60 | .007 |
NA, not available.
Genotype 4–infected patients were not modeled separately as there were too few for robust multivariable models.
AOR, adjusted odds ratio, by multivariable logistic regression modeling including the following variables: age, sex, race/ ethnicity, history of alcohol use disorders, HCV genotype and subgenotype, HCV regimen, baseline HCV viral load, diabetes, treatment naïve/experienced, cirrhosis, decompensated cirrhosis, HCC, liver transplantation, platelet count, serum bilirubin and albumin levels.
The effect of regimen on SVR was estimated using augmented inverse-probability-weighted logistic regression to account for the propensity of receiving each regimen.